Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors).

Int J Gynecol Cancer

*Kliniken-Essen-Mitte, AGO, Essen, Germany; †MD Andersen Cancer Center, GOG, Houston, TX; ‡Gustave Roussy, GINECO, Villejuif Cedex, France; §Université René Descartes, GINECO, Paris, France; ∥UCL Cancer Institute, MRC NCRI, London, United Kingdom; ¶CHUM-Notre-Dame Hospital, NCIC-CTG, Montreal, Quebec, Canada; #Fondazione IRCCS Istituto Nazionale dei Tumori, MITO, Milan, Italy; **ANZGOG, Parkville, Victoria, Australia; ††University and University Hospital of Tampere, NSGO, Tampere, Finland; ‡‡Seoul National University, KGOG, Seoul, South Korea; §§University Medical Center Hamburg-Eppendorf, AGO, Hamburg, Germany; ∥∥University Hospital Kiel, AGO, Kiel, Germany; ¶¶UKGM, Marburg, AGO, Marburg, Germany; and ##Gynecologic Oncology Center, Kiel, AGO, Kiel, Germany.

Published: November 2014

Since the early 1970s, the World Health Organization and the International Federation of Gynecology and Obstetrics have classified borderline ovarian tumors as an independent group of ovarian epithelial tumors. A consensus statement of the Gynecologic Cancer Intergroup is reported.

Download full-text PDF

Source
http://dx.doi.org/10.1097/IGC.0000000000000282DOI Listing

Publication Analysis

Top Keywords

ovarian tumors
12
gynecologic cancer
8
cancer intergroup
8
borderline ovarian
8
intergroup gcig
4
gcig consensus
4
consensus review
4
ovarian
4
review ovarian
4
tumors
4

Similar Publications

Only a few human ovarian endometrioid carcinoma cell lines are currently available, partly due to the difficulty of establishing cell lines from low-grade cancers. Here, using a cell immortalization strategy consisting of i) inactivation of the p16-pRb pathway by constitutive expression of mutant cyclin-dependent kinase 4 (R24C) (CDK4) and cyclin D1, and ii) acquisition of telomerase reverse transcriptase (TERT) activity, we established a human ovarian endometrioid carcinoma cell line from a 46-year-old Japanese woman. That line, designated JFE-21, has proliferated continuously for over 6 months with a doubling time of ~ 55 h.

View Article and Find Full Text PDF

The role of Anti-Müllerian hormone in women health.

Ginekol Pol

January 2025

Department of Clinical Dietetics, Faculty of Health Sciences, Medical University of Warsaw, Poland, Poland.

Anti-Müllerian hormone (AMH), also known as Müller duct inhibitory factor and primarily known for its role in sexual differentiation. In female fetuses, AMH production by granulosa cells begins around the 36th week of gestation and continues in women until menopause. It is becoming more significant in the endocrine and gynecological diagnosis of adult women.

View Article and Find Full Text PDF

Comprehensive evaluation of genomic and functional assays for homologous recombination deficiency with high-grade epithelial ovarian cancer: Platinum sensitivity and prognosis.

Int J Gynecol Cancer

January 2025

Fudan University Shanghai Cancer Center, Department of Gynecologic Oncology, Shanghai, China; Fudan University, Shanghai Medical College, Department of Oncology, Shanghai, China. Electronic address:

Objective: Homologous recombination deficiency assays, guiding treatment of poly (adenosine diphosphate ribose) polymerase inhibitors, are increasingly applied in clinics. This study aimed to evaluate the predictive performance of homologous recombination deficiency status at genomic and functional perspective on the efficacy of platinum-based chemotherapy in ovarian cancer.

Methods: Between 2016 and 2019, 134 patients with high-grade ovarian cancer were retrospectively analyzed.

View Article and Find Full Text PDF

Prognostic significance and accuracy of oncologists' estimates of survival time in recurrent ovarian cancer.

Int J Gynecol Cancer

January 2025

The NHMRC Clinical Trials Centre, The University of Sydney, Sydney, NSW, Australia; Macarthur Cancer Therapy Centre, Sydney, NSW, Australia; Western Sydney University, Department of Medicine, Sydney, NSW, Australia. Electronic address:

Objective: We evaluated the accuracy of oncologists' estimates of expected survival time in recurrent ovarian cancer.

Methods: Oncologists estimated expected survival time at baseline for each patient, who were then followed up for survival time. We hypothesized that oncologists' estimates of expected survival time would be independently significant predictors of survival, unbiased (approximately equal proportions [50%] living longer versus shorter than their expected survival time), or imprecise (<30% within 0.

View Article and Find Full Text PDF

Role of pre-diagnostic reproductive factors on long-term (10 years or greater) survival of epithelial ovarian cancer: The Extreme study.

Int J Gynecol Cancer

January 2025

Danish Cancer Institute, Virus, Lifestyle and Genes, Copenhagen, Denmark; University of Copenhagen, Department of Clinical Medicine, Copenhagen, Denmark; Rigshospitalet, Copenhagen University Hospital, Department of Gynecology, Copenhagen, Denmark. Electronic address:

Objective: Several reproductive factors are associated with ovarian cancer risk but the association with survival is less clear. The main aim was to examine the impact of pre-diagnostic reproductive factors on long-term ovarian cancer survival (≥10 years).

Methods: We included all women with epithelial ovarian cancer in Denmark, 1990-2014.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!